International Recommendations on Postoperative Management for Potentially Resectable Locally Recurrent Nasopharyngeal Carcinoma.

Nasopharyngeal carcinoma guideline postoperative management re-irradiation recurrence resectability

Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
13 Jul 2024
Historique:
received: 07 11 2023
revised: 25 05 2024
accepted: 01 07 2024
medline: 16 7 2024
pubmed: 16 7 2024
entrez: 15 7 2024
Statut: aheadofprint

Résumé

Locally recurrent nasopharyngeal carcinoma (NPC) presents substantial challenges in clinical management. While postoperative re-irradiation (re-RT) has been acknowledged as a potential treatment option, standardized guidelines and consensus regarding the use of re-RT in this context are lacking. This article provides a comprehensive review and summary of international recommendations on postoperative management for potentially resectable locally recurrent NPC, with a special focus on postoperative re-RT. A thorough search was conducted to identify relevant studies on postoperative re-RT for locally recurrent NPC. Controversial issues, including resectability criteria, margin assessment, indications for postoperative re-RT, and the optimal dose and method of re-RT, were addressed through a Delphi consensus process. The consensus recommendations emphasize the need for a clearer and broader definition of resectability, highlighting the importance of achieving clear surgical margins, preferably through an en bloc approach with frozen section margin assessment. Furthermore, these guidelines suggest considering re-RT for patients with positive or close margins. Optimal postoperative re-RT doses typically range around 60Gy, and hyperfractionation has shown promise in reducing toxicity. These guidelines aim to assist clinicians in making evidence-based decisions and improving patient outcomes in the management of potentially resectable locally recurrent NPC. By addressing key areas of controversy and providing recommendations on resectability, margin assessment, and re-RT parameters, these guidelines serve as a valuable resource for the clinical experts involved in the treatment of locally recurrent NPC. This article provides international recommendations on postoperative management for potentially resectable locally recurrent nasopharyngeal carcinoma (NPC), with a special focus on postoperative re-irradiation (re-RT). The consensus guidelines highlight the importance of achieving clear surgical margins, suggest considering re-RT for patients with positive or close margins, recommend an optimal re-RT dose of around 60Gy, and propose the use of hyperfractionation to reduce toxicity. The aim is to improve patient outcomes in the management of resectable locally recurrent NPC.

Identifiants

pubmed: 39009321
pii: S0360-3016(24)02954-7
doi: 10.1016/j.ijrobp.2024.07.2143
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest W.T. Ng, Anne W.M. Lee and Ji-Shi Li are supported Shenzhen Key Medical Discipline Construction Fund (No. SZXK014), Shenzhen Science and Technology Program (Grant No. KQTD20180411185028798), Department of Clinical Oncology, Shenzhen Key Laboratory for cancer metastasis and personalized therapy, The University of Hong Kong-Shenzhen Hospital

Auteurs

Ji-Shi Li (JS)

Department of Clinical Oncology, Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

Pierre Blanchard (P)

Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Charlene H L Wong (CHL)

Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Electronic address: wonghlc@hku.hk.

Yong Chan Ahn (YC)

Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Pierluigi Bonomo (P)

Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Damien Bresson (D)

Department of Neurosurgery, Hôpital Foch, Suresnes, France.

Jimmy Caudell (J)

Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA.

Ming-Yuan Chen (MY)

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.

Velda L Y Chow (VLY)

Division of Head and Neck Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, China.

Melvin L K Chua (MLK)

Department of Head and Neck and Thoracic Radiation Oncology; Precision Radiotherapeutics Oncology Programme, Division of Medical Sciences, National Cancer Centre Singapore; Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore.

June Corry (J)

Division of Radiation Oncology, GenesisCare Radiation Oncology, St. Vincent's Hospital, Melbourne, Victoria, Australia.

Charles Dupin (C)

Department of Radiation Oncology, Bordeaux University Hospital, F33000 Bordeaux, France.

Jordi Giralt (J)

Department of Radiation Oncology, Vall D'Hebron University Hospital, Barcelona, Spain.

Chaosu Hu (C)

Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China.

Dora L W Kwong (DLW)

Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Quynh-Thu Le (QT)

Department of Radiation Oncology, Stanford University, Stanford, CA, USA.

Anne W M Lee (AWM)

Department of Clinical Oncology, Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

Nancy Y Lee (NY)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.

Youzhong Li (Y)

The Second Xiangya Hospital of Central South University, Department of Otorhinolaryngology, Head and Neck Surgery, Changsha, China.

Chwee Ming Lim (CM)

Department of Otolaryngology-Head and Neck Surgery, Singapore General Hospital, Singapore.

Jin-Ching Lin (JC)

Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan.

William M Mendenhall (WM)

Department of Radiation Oncology, University of Florida, Gainesville, Florida, USA.

A Moya-Plana (A)

Department of Head and Neck Oncology, Gustave Roussy, Villejuif, France.

Brian O'Sullivan (B)

Department of Otolaryngology-Head and Neck Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

Enis Ozyar (E)

Acibadem MAA University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey.

Jianji Pan (J)

Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou, China.

Qianhui Qiu (Q)

Department of Otolaryngology, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, China.

David J Sher (DJ)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, USA.

Carl H Snyderman (CH)

Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, USA.

Yungan Tao (Y)

Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Raymond K Tsang (RK)

Department of Otolaryngology- Head and Neck Surgery, National University of Singapore, Singapore.

Xiaoshen Wang (X)

Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China.

Pingan Wu (P)

Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

Sue S Yom (SS)

Department of Radiation Oncology, University of California San Francisco, San Francisco, California, USA.

Wai Tong Ng (WT)

Department of Clinical Oncology, Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Electronic address: ngwt1@hku.hk.

Classifications MeSH